Investigational drug · Phase 2
JR-446
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Mucopolysaccharidosis III-B, Mucopolysaccharidosis IIIB.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "JR-446"
First trial start
2024
Nov 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JR-446", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mucopolysaccharidosis III-B
- Mucopolysaccharidosis IIIB
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "JR-446" as an intervention, largest first.
JCR Pharmaceuticals Co., Ltd.Industry
NCT07640984 · 12 participants (planned) · Start Sep 9, 2026 · Primary completion Jun 30, 2028
Drug: JR-446 · For: Mucopolysaccharidosis IIIB
Sites: Oakland, California; Pittsburgh, Pennsylvania; Fairfax, Virginia · 5 sites in all
- An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIBActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT06488924 · 10 participants (planned) · Start Nov 5, 2024 · Primary completion Apr 30, 2030
Drug: JR-446 · For: Mucopolysaccharidosis III-B
Sites: Hiroshima, Japan; Okinawa, Japan; Tokyo, Japan · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.